Announced Tue, 18 Aug · 12:39 IST
Sudarshan Pharma files August 2026 investor presentation, PAT doubles in FY26
Mgmt Guided Margin ImprovementAnalyst Day Multiyear TargetsOrder Pipeline DisclosedInvestor Communications View source PDFExplain this filing
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+4.0%1-day move
₹35.60
prior close
—
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————+4.0+7.4+7.3———————
Up moveDown movePending
AI summary
Sudarshan Pharma filed August 2026 investor presentation. FY26 revenue up 39 percent to Rs 703 Cr, PAT doubled to Rs 23.4 Cr. Q1 FY27 revenue Rs 174 Cr, PAT Rs 5.6 Cr, EBITDA margin improved to 9.81 percent from 8.43 percent. Management targets minimum Rs 100 Cr exports in FY27 versus Rs 21.85 Cr in FY26. New CFO appointed. Plans include USD 20 Million FCCB, Hyderabad unit acquisition, Amity University R&D partnership.
Likely market impact
Strong revenue and margin growth, aggressive FY27 export target, fresh leadership. Positive read on scale-up story for this BSE SME-listed pharma company.